Novavax (NVAX) Total Liabilities (2010 - 2026)
Novavax (NVAX) posted quarterly Total Liabilities of $1.2 billion for Q1 2026, down 13.2% year-over-year from $1.4 billion in Q1 2025, and down 8.92% quarter-over-quarter from $1.3 billion in Q4 2025.
Novavax (NVAX) Total Liabilities (2010 - 2026) Analysis & Trends
Novavax's Total Liabilities history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Total Liabilities fell 13.2% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (down 13.2% YoY), while the FY2025 annual figure was $1.3 billion, down 40.29% from the prior year.
- Total Liabilities for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
- The five-year high for Total Liabilities was $3.0 billion in Q2 2022, with the low at $1.2 billion in Q1 2026.
- The 5-year median for Total Liabilities is $2.3 billion (2024), against an average of $2.2 billion.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 76.49% in 2022, then slumped 42.28% in 2025.
- Novavax's Total Liabilities stood at $2.9 billion in 2022, then declined by 13.08% to $2.5 billion in 2023, then slipped by 13.13% to $2.2 billion in 2024, then plunged by 40.29% to $1.3 billion in 2025, then declined by 8.92% to $1.2 billion in 2026.
- Business Quant data shows NVAX's Total Liabilities at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 1.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.15 Bn |
| Mar 31, 2026 | 1.19 Bn |
| Dec 31, 2025 | 1.30 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Mar 31, 2025 | 1.37 Bn |
| Dec 31, 2024 | 2.18 Bn |
| Sep 30, 2024 | 2.24 Bn |
| Jun 30, 2024 | 2.25 Bn |
| Mar 31, 2024 | 2.22 Bn |
| Dec 31, 2023 | 2.51 Bn |
| Sep 30, 2023 | 2.34 Bn |
| Jun 30, 2023 | 2.44 Bn |
| Mar 31, 2023 | 2.44 Bn |
| Dec 31, 2022 | 2.89 Bn |
| Sep 30, 2022 | 2.83 Bn |
| Jun 30, 2022 | 3.04 Bn |
| Mar 31, 2022 | 2.77 Bn |
| Dec 31, 2021 | 2.93 Bn |
| Sep 30, 2021 | 2.10 Bn |